MapLight Therapeutics, a biotech focused on neurological diseases, has filed for an initial public offering to list on Nasdaq under 'MPLT.' The company is advancing its lead drug candidate targeting muscarinic receptors for schizophrenia and Alzheimer’s disease psychosis. These agents modulate neurotransmitter release and are intended to offer improved dosing convenience and fewer side effects compared to current therapies. MapLight aims to provide new treatment options addressing unmet needs in neuropsychiatric disorders and expects clinical trial readouts through 2026-2027.